Befotinib
Phase 2
Befotinib is one of 5 therapeutic programs targeting Advanced Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Advanced Non-Small Cell Lung Cancer (NSCLC)
#DrugCompanyPhaseTrials
1Tagrisso
AstraZenecaPhase 2
Platinum Chemotherapy
RochePhase 2
Befotinib
GGuangzhou University of Traditional Chinese Medicine
Phase 2
AK112
SSummit Therapeutics
Preclinical
AMT-116
MMultitude Therapeutics Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Non-Small Cell Lung Cancer (NSCLC)1 trial
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 2·NCT07709585·124 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Befotinib. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]